No Treatment Required – This Patient Does Not Have Diabetes or Prediabetes
This patient with fasting glucose 114 mg/dL and A1C 5.2% does not meet criteria for diabetes or prediabetes and requires no pharmacologic treatment. The focus should be on lifestyle counseling for primary prevention of cardiovascular disease and type 2 diabetes.
Diagnostic Classification
This patient's values fall into the following categories:
- A1C 5.2%: Normal (prediabetes begins at ≥5.7%) 1, 2
- Fasting glucose 114 mg/dL: Technically meets criteria for impaired fasting glucose (IFG), which is defined as 100-125 mg/dL 1
However, the A1C takes precedence in this discordant scenario. The A1C of 5.2% indicates normal average glycemia over the past 2-3 months and does not support a diagnosis of prediabetes, which requires A1C 5.7-6.4% 1, 2.
Why A1C Matters More Here
- A1C reflects integrated glucose exposure over time, not a single point measurement
- Fasting glucose can be transiently elevated by stress, recent illness, inadequate fasting, or laboratory variation
- Guidelines consistently define prediabetes as A1C 5.7-6.4% or IFG or impaired glucose tolerance 1, 2
- When markers are discordant, the A1C provides more reliable risk stratification 3
Recommended Management
1. Lifestyle Counseling (Primary Prevention)
Since this patient has one borderline glucose value, provide cardiovascular risk reduction counseling 4, 5:
Physical Activity:
- Goal: At least 150 minutes per week of moderate-intensity aerobic activity (brisk walking, 15-20 min/mile pace)
- Add resistance training 2 days per week with 8-10 exercises, 10-15 repetitions 4, 5
Weight Management:
- Assess BMI and waist circumference
- If BMI ≥25 kg/m² or waist circumference ≥40 inches (men) or ≥35 inches (women), initiate weight management through caloric restriction and increased activity 4, 5
- Target BMI 18.5-24.9 kg/m²
Dietary Pattern:
- Heart-healthy eating pattern: Mediterranean, DASH, or vegetarian/vegan diet
- Reduce saturated fats and refined carbohydrates 5
2. No Pharmacologic Therapy Indicated
Metformin is NOT recommended for this patient. Guidelines reserve metformin for prediabetes (A1C 5.7-6.4%), particularly in those with 1, 2:
- BMI >35 kg/m²
- Age <60 years
- Prior gestational diabetes
- Higher-risk prediabetes (A1C ≥6.0% or fasting glucose ≥110 mg/dL)
This patient's A1C of 5.2% places them well below the threshold for any glucose-lowering intervention.
3. Follow-Up Monitoring
- Repeat screening in 3 years if no risk factors develop 2
- Screen annually if the patient develops obesity, family history of diabetes, or other diabetes risk factors
- Use A1C and/or fasting glucose for screening 1
Important Caveats
When to Suspect A1C Unreliability
The A1C may be falsely low or high in conditions affecting red blood cell turnover 6, 7:
- Falsely low: Hemolytic anemia, recent blood loss, chronic kidney disease, hemoglobinopathies
- Falsely high: Iron deficiency anemia, vitamin B12 deficiency
If clinical suspicion exists for glucose dysregulation despite normal A1C, consider:
- Oral glucose tolerance test (OGTT)
- Continuous glucose monitoring (CGM) 7
- Evaluation for conditions affecting erythrocyte lifespan
Confirm the Fasting State
Ensure the glucose was truly fasting (≥8 hours, water only). If uncertain, repeat fasting glucose before making any clinical decisions.
Cardiovascular Risk Factor Screening
Since this patient is being evaluated for metabolic parameters, assess other ASCVD risk factors 4, 5:
- Blood pressure (goal <130/80 mm Hg if other risk factors present)
- Lipid panel (LDL-C, HDL-C, triglycerides)
- Smoking status
- Calculate 10-year ASCVD risk if age ≥40 years
Treat any identified cardiovascular risk factors according to current guidelines, independent of glucose status.